Progress in Pharmacogenetics
On 13 October, the PSY-PGx consortium held its annual General Assembly in Amsterdam. The event gathered representatives from 16 partner sites across 12 countries. The consortium continues to make excellent progress in the implementation of pharmacogenetics in psychiatry.
At present, eight clinical sites are actively recruiting patients in six countries. This marks an important milestone in this pioneering international research initiative.
Representing the Patient Voice
GAMIAN-Europe was represented by Erik Van der Eycken, who ensured that the patient perspective was included throughout the discussions. His participation highlighted the importance of patient involvement in shaping the future of pharmacogenetics in mental health care.
Our role in PSY-PGx reflects our ongoing commitment to patient-centred research, where lived experience helps design and deliver innovative, effective treatments.
About the PSY-PGx Project
PSY-PGx is the first large-scale, non-industry-sponsored research project to explore how genes interact with medication in psychiatry. Funded by the European Union’s Horizon 2020 programme, the project brings together partners from 11 European countries and the United States. Together, they aim to improve psychiatric care, reduce patient suffering, and ease the wider economic burden of mental ill health.
Collaboration Across Europe
The meeting welcomed leading consortium members, including Thomas G. Schulze, Allan Young, Mario F. Juruena, Daniel Silman, Marin Jukic, Ramona Moldovan, Andra Ciucă, Magnus Ingelman-Sundberg, Jaakko Kaprio, Noam Shomron, Prof. Dr. med. Alexandra Philipsen, Jonathan Laatsch, Urs Heilbronner, Monika Budde, Eduard Vieta, Natalia E. Fares-Otero, Martien Kas, Raj Jagesar, Markus Nöthen, Per Hoffmann, Kristian Kleine Schaars and Sanah Bedi.
Looking Ahead
GAMIAN-Europe is proud to contribute to this international collaboration. We will continue to ensure that the voices of patients remain central as pharmacogenetic research moves closer to transforming psychiatric treatment.
GAMIAN-Europe is proud to contribute to this international collaboration and will continue to ensure that the voices of patients remain central as pharmacogenetic research advances towards transforming psychiatric treatment.
To learn more about the PSY-PGx project, please visit the official website.
For more information on GAMIAN-Europe’s ongoing projects and initiatives, please follow its social media LinkedIn, Facebook, X, Instagram, Bluesky and YouTube.
If you are new here, feel free to read what we do.